Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of lung cancer, especially in the first-line treatment of advanced NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiaotong, Cao, Luchang, Ni, Baoyi, Wang, Jia, Qin, Xiaoyan, Sun, Xiaoyue, Xu, Bowen, Wang, Xinmiao, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120859/
https://www.ncbi.nlm.nih.gov/pubmed/37089959
http://dx.doi.org/10.3389/fphar.2023.1090500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120859/
https://www.ncbi.nlm.nih.gov/pubmed/37089959
http://dx.doi.org/10.3389/fphar.2023.1090500

Ejemplares similares